May 2026
đź“Ł VC round data is live. Check it out!
Largest Medical Devices Public Companies in Germany
Benchmark revenue and EBITDA valuation multiples for public comps like
Siemens, Siemens Healthineers, Fresenius Medical Care, Ottobock and Carl Zeiss Meditec.
 | Siemens is a multi-industry company focused on the areas of automation, electrification, mobility, and healthcare. Its top three geographic regions—the United States, Germany, and China—contribute over half of group revenue. Siemens has a 71% investment in separately listed Siemens Healthineers. Recent portfolio activity included the listing of Siemens Energy, spinning out its power and gas and Siemens Gamesa business divisions in 2020. | $312 | +28% | $238B | $275B | 3.0x | 15.0x | ||
| Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (56% of sales in fiscal 2025) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (18% of sales) offers radiotherapy and other oncology solutions. The diagnostics segment (19%) includes in vitro diagnostics and point-of-care diagnostics. The advanced therapies (now part of precision therapy) segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. The Americas represents 44% of total sales, Europe, Middle East, and Africa 32%, and Asia-Pacific, including China (11%), the remainder. | $40 | -25% | $45B | $43B | 1.6x | 7.9x | ||
| Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments. | $43 | -25% | $12B | $23B | 1.0x | 5.3x | ||
| Ottobock SE & Co KGaA is a medical technology company. It specializes in products and services designed to improve mobility and quality of life for people with disabilities or limited mobility. The company's portfolio includes prosthetics, orthotics, neuro-orthotics, rehabilitation products, wheelchairs, and bionic exoskeletons. Ottobock operates a network of patient care centers and service locations in various countries, providing tailored solutions and support to users. The company’s geographical segments include Europe, the Middle East and Africa (EMEA), the Americas, and Asia Pacific (APAC), generating the majority of revenue from the EMEA segment. | $65 | -- | $4B | $5B | 2.9x | 15.8x | ||
| Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space. | $31 | -54% | $3B | $3B | 1.1x | 6.6x | ||
| Draegerwerk AG & Co KGaA develops medical and safety equipment for clinical and industrial applications. The firm operates in two segments: medical and safety. The medical division contributes the majority of revenue, it develops and produces system solutions, equipment, and services for the acute point of care, it has five business units Therapy, Hospital Consumables & Accessories, Workplace Infrastructure, Monitoring, and Data Business. Its safety division develops and produces devices, system solutions, and services for personal protection, gas detection, and integrated hazard management. Its geographical segments are Europe; Germany; the Americas; Africa, Asia, and Australia. | $95 | +35% | $2B | $2B | 0.4x | 4.0x | ||
| Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions. | $34 | +331% | $1B | $1B | 170.8x | 256.0x | ||
| Medios AG is engaged as a wholesaler for pharmaceutical medicinal products. The operating segments of the company includes: Patient-Specific Therapies: This area includes the compounding of medications on behalf of pharmacies in Germany. Pharmaceautical Supply: Medios is speciality pharma supplier company in germany, producing it own production facilities, hospitals, and Pharmacies. International Business: It includes all business and activities happening in international business. | $16 | +17% | $402M | $556M | 0.3x | 7.5x | ||
| Stratec SE designs and manufactures automated analyzer systems for laboratory data management and solutions for molecular diagnostic sample preparation and stabilization. Its business segments are Instrumentation, Diatron and Smart Consumables. Its Instrumentation segment is engaged in designing and manufacturing automated analyzer systems for clinical diagnostics and biotechnology customers. The Diatron segment comprises the business with systems, system components, consumables, and tests in the low throughput hematology and clinical chemistry segment. Its Smart Consumables segment is engaged in developing and selling scientific materials, such as nucleic acid purification. The company generates maximum revenue from the Instrumentation segment. | $20 | -38% | $243M | $368M | 1.3x | 9.4x | ||
| Viromed Medical AG is a medical technology company. It focuses on using cold plasma technology to develop medical solutions that protect people from viruses, bacteria, and multi-resistant germs. Viromed's product offerings include ViroCAP, a medical device based on cold plasma technology for treating wounds; ViroCAP derma-podo, a medical device that uses cold atmospheric plasma therapy for skin and foot care; and a Raumluftentkeimer. The company covers the entire value chain from research and development to production, logistics, marketing, and sales of its products. | $7 | -- | $149M | $149M | — | (605.0x) | ||
| Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. | $2 | -15% | $62M | $56M | 519.5x | (3.1x) | ||
| aap Implantate AG develops, manufactures, and markets trauma products for orthopedics. The company classifies its products that are Trauma and Others. The product line of the company consists of a plating system under the brand LOQTEQ, and cannulated screws. The company's projects such as antibacterial silver coating technology and magnesium-based implants. It develops a plating system for the Shoulder, Knee, Elbow, Wrist, and Ankle Joint. The company sells its product directly to hospitals, syndicates, and hospital groups with the help of distributors. | $2 | +55% | $35M | $34M | 2.4x | (44.4x) | ||
| NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use. | $2 | +18% | $24M | $16M | 2.9x | (4.0x) | ||
| Geratherm Medical AG is a Germany-based medical technology company. The firm operates through four segments: Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Healthcare Diagnostic segment which generates majority revenue provides analog and digital products for measuring body temperature, blood pressure monitors and other products for measuring temperature, as well as related accessories. Medical Warming Systems offers solutions for temperature management at all stages in the pre-clinical and clinical care of the patients, such as rescue situations and operations. Cardio/Stroke segment comprises products for preventing strokes. The Respiratory segment focuses on the development and production of products for pulmonary functional diagnostics. | $3 | -9% | $18M | $10M | 0.4x | 2.7x | ||
| Bio-Gate AG is a Germany based medical technology company. The company employs silver technology to endow materials and products with antimicrobial properties. It is focused on the medical technology products portfolio. In addition, its technologies are also used to refine cosmetics, consumer goods, and industrial products. The products of the company are plasma-coating, additives, textile solutions, spray, masterbatches, and others. The organization uses two different technologies; first, silver particles are incorporated into cosmetics, paints, veneers or plastics, and second involve coating final products like implants or wound dressings with a silver-containing functional layer. | $1 | -30% | $8M | $7M | 0.9x | (4.8x) | ||
| Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia. | $1 | -11% | $886K | $14M | 488.7x | (37.4x) | ||
| Median | $18 | -10% | $323M | $462M | 1.6x | 4.7x |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.